CD52 Targeted Therapies
2 drugsAbout CD52
CD52 is a glycoprotein highly expressed on lymphocytes, making it a target for immunosuppressive therapies. While its precise function is still being researched, its abundance on immune cells makes it an attractive target.
CD52 has clinical viability in autoimmune diseases and certain cancers, but there is currently no genetic evidence directly linking CD52 to specific diseases.
CD52 is targeted by two FDA-approved antibody drugs, LEMTRADA and CAMPATH, both marketed by Sanofi, for CNS and other indications.
Top CD52 Drugs
Sanofi is the only company with approved drugs targeting CD52.
High market concentration suggests high entry barriers or limited commercial opportunity.
CD52 Drug Modality Landscape
Modalities
Routes of Administration
CD52 is exclusively targeted by antibodies, suggesting it may be a cell-surface or secreted protein.
Explore alternative modalities like small molecules to differentiate from existing therapies.
CD52 Clinical Trials 101 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on CD52. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 38 | 15 | 7 | 16 | 68% |
| Phase 2 | 51 | 17 | 15 | 18 | 53% |
| Phase 3 | 5 | 3 | 1 | 1 | 75% |
| Phase 4 | 7 | 6 | 1 | 0 | 86% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
CD52 Drug Approval Timeline (2001 - 2001)
The first CD52-targeting drug was approved in 2001, with the most recent approval in the same year.
The lack of recent approvals indicates a potentially saturated market or challenges in developing new CD52-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 57 (5 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on CD52. A trial counts if an approved drug acting on CD52 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.